SCHEMBL989830

SCHEMBL989830

CN1CCC(C#N)(CC#N)CC1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 5/20 0.37
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
RECQL P46063 1/20 0.35
KDM1A O60341 1/20 0.32
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25094688 0.80 OPRM1 (0.38) OPRM1KMT2AALDH1A1KDM4EMEN1
SCHEMBL25728476 0.78 OPRM1 (0.37) OPRM1KMT2AALDH1A1KDM4EMEN1
SCHEMBL29057634 0.78 OPRM1 (0.37) OPRM1KMT2AALDH1A1KDM4EMEN1
SCHEMBL25338300 0.78
SCHEMBL1504251 0.74
SCHEMBL3494205 0.74 ALDH1A1 (0.36) ALDH1A1
SCHEMBL2069655 0.72 ALDH1A1 (0.40) ALDH1A1
SCHEMBL3495531 0.72 ALDH1A1 (0.40) ALDH1A1
SCHEMBL17077903 0.70
SCHEMBL23555793 0.70 OPRM1 (0.35) OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210338849-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2021-11-04 US disclosed
EP-3231804-B1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2021-03-03 EP disclosed
US-10857247-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders THE GENERAL HOSPITAL CORPORATION (US) 2020-12-08 US disclosed
CN-104974024-B Detection and the compound and composition for the treatment of Alzheimer disease and relevant disease 综合医院公司 2017-11-14 CN disclosed
EP-3231804-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS The General Hospital Corporation (US) 2017-10-18 EP disclosed
EP-2268647-B1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS MASSACHUSETTS GEN HOSPITAL (US) 2017-01-25 EP disclosed
CN-104974024-A Compounds and compositions for detection and treatment of alzheimer's disease and related disorders GEN HOSPITAL CORP 2015-10-14 CN disclosed
CN-102046638-B Compounds and compositions for detecting and treating alzheimer's disease and related disorders GEN HOSPITAL CORP 2015-06-03 CN disclosed
US-9005578-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders FLUOROPHARMA, INC. (US) 2015-04-14 US disclosed
US-20150098903-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders THE GENERAL HOSPITAL CORPORATION 2015-04-09 US disclosed
US-20130315827-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders FLUOROPHARMA, INC. (US) 2013-11-28 US disclosed
US-8450466-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders THE GENERAL HOSPTIAL CORPORATION (US) 2013-05-28 US disclosed
US-20110060138-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders THE GENERAL HOSPITAL CORPORATION 2011-03-10 US disclosed
EP-2268647-A2 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS The General Hospital Corporation (US) 2011-01-05 EP disclosed
WO-2009117728-A2 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338849-A1 COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS APP, PSEN1, PSEN2 OPRM1 4483/4885KMT2A 2940/4885ALDH1A1 877/4885
US-10857247-B2 Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders APP, PSEN1, PSEN2 OPRM1 4483/4885KMT2A 2940/4885ALDH1A1 877/4885
US-20130315827-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 OPRM1 4483/4885KMT2A 2940/4885ALDH1A1 877/4885
US-20150098903-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 OPRM1 4483/4885KMT2A 2940/4885ALDH1A1 877/4885
US-20110060138-A1 Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders APP, PSEN1, PSEN2 OPRM1 4483/4885KMT2A 2940/4885ALDH1A1 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.